|
[1]
|
Feng XY, Levens J, Zhou XN. Protecting the gains of malaria elimination in China. Infect Dis Poverty 2020;9(1):43. http://dx.doi.org/10.1186/s40249-020-00661-yCrossRef
|
|
[2]
|
Zhang L, Feng J, Zhang SS, Xia ZG, Zhou SS. The progress of national malaria elimination and epidemiological characteristics of malaria in China in 2017. Chin J Parasitol Parasit Dis 2018; 36(3): 201-9. https://d.wanfangdata.com.cn/periodical/zgjscxyjscbzz201803001. (In Chinese). https://d.wanfangdata.com.cn/periodical/zgjscxyjscbzz201803001 |
|
[3]
|
Yin JH, Yan H, Huang F, Li M, Xiao HH, Zhou SS, et al. Establishing a China malaria diagnosis reference laboratory network for malaria elimination. Malar J 2015;14(1):40. http://dx.doi.org/10.1186/s12936-015-0556-zCrossRef
|
|
[4]
|
White NJ. Antimalarial drug resistance. J Clin Invest 2004;113(8):1084 − 92. http://dx.doi.org/10.1172/JCI21682CrossRef
|
|
[5]
|
WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization. 2009. https://www.who.int/malaria/publications/atoz/9789241597531/en/.https://www.who.int/malaria/publications/atoz/9789241597531/en/ |
|
[6]
|
WHO. Malaria surveillance, monitoring & evaluation: a reference manual. Geneva: World Health Organization. 2009. https://www.who.int/malaria/publications/atoz/9789241565578/en/.https://www.who.int/malaria/publications/atoz/9789241565578/en/ |
|
[7]
|
Huang F, Tang LH, Yang HL, Zhou SS, Sun XD, Liu H. Therapeutic efficacy of artesunate in the treatment of uncomplicated Plasmodium falciparum malaria and anti-malarial, drug-resistance marker polymorphisms in populations near the China-Myanmar border. Malar J 2012;11(1):278. http://dx.doi.org/10.1186/1475-2875-11-243CrossRef
|
|
[8]
|
Huang F, Tang L, Yang H, Zhou S, Liu H, Li J, Guo S. Molecular epidemiology of drug resistance markers of Plasmodium falciparum in Yunnan Province, China. Malar J 2012;11(1):243. http://dx.doi.org/10.1186/1475-2875-11-278CrossRef
|
|
[9]
|
Liu H, Yang HL, Tang LH, Li XL, Huang F, Wang JZ, et al. In vivo monitoring of dihydroartemisinin-piperaquine sensitivity in Plasmodium falciparum along the China-Myanmar border of Yunnan Province, China from 2007 to 2013. Malar J 2015;14(1):47. http://dx.doi.org/10.1186/s12936-015-0584-8CrossRef
|
|
[10]
|
van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis 2019;19(9):952 − 961. http://dx.doi.org/10.1016/S1473-3099(19)30391-3CrossRef
|
|
[11]
|
WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy. Geneva: World Health Organization; 2018. https://www.who.int/publications/i/item/status-report-on-artemisinin-resistance-and-act-efficacy.https://www.who.int/publications/i/item/status-report-on-artemisinin-resistance-and-act-efficacy |
|
[12]
|
Ferreira MU, Nobrega de Sousa T, Rangel GW, Johansen IC, Corder RM, Ladeia-Andrade S, Gil JP. Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions. Int J Parasitol Drugs Drug Resist 2021;15:9 − 24. http://dx.doi.org/10.1016/j.ijpddr.2020.12.001CrossRef
|
|
[13]
|
Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, et al. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 2001;344(4):257 − 63. http://dx.doi.org/10.1056/NEJM200101253440403CrossRef
|
|
[14]
|
Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis 2015;211(8):1352 − 5. http://dx.doi.org/10.1093/infdis/jiu608CrossRef
|
|
[15]
|
Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 2017;17(2):174 − 83. http://dx.doi.org/10.1016/S1473-3099(16)30415-7CrossRef
|